{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:10:07Z","timestamp":1767179407474,"version":"build-2238731810"},"update-to":[{"DOI":"10.1371\/journal.pntd.0013719","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000}}],"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>\n                    African trypanosomiasis remains a critical public health concern, with over 55 million people still at risk of infection. There are several issues associated with the current therapies including toxicity and resistance, which represent the main bottleneck of trypanosomiasis control. Thus, it is urgent to develop novel therapeutic tools with distinct mechanisms of action. The\n                    <jats:italic>in vitro<\/jats:italic>\n                    phenotypic screening of the Merck KGaA Darmstadt German Open Global Health Library (OGHL) against\n                    <jats:italic>Trypanosoma brucei brucei<\/jats:italic>\n                    yielded three potent kinase inhibitors belonging to different chemical series: a phenylcarbonylacrylamide (OGHL00006); a 2,4-di(phenylamino)pyrimidine (OGHL00133); and a 3-(triazol-4-yl)-7-azaindole (OGHL00169). They exhibited low micromolar to nanomolar median inhibitory concentrations (IC\n                    <jats:sub>50<\/jats:sub>\n                    values of 0.6 \u00b5M, 0.007 \u00b5M, and 0.25 \u00b5M, respectively) and good selectivity when tested on Vero cells (SI &gt; 2). OGHL00006 and OGHL00169 induced a rapid and irreversible growth arrest of\n                    <jats:italic>T. b. brucei<\/jats:italic>\n                    within 4\u201324 hours of incubation. Interestingly, these two hits have also been reported to display antiplasmodial and\/or anthelminthic activities, hinting at a similar mechanism of action across multiple species. Given the significant sequence similarities between the human and trypanosome kinomes, we rationalized the putative mechanisms of action for the identified hits through comparative modeling of protein\u2013ligand complexes. This study suggests promising avenues for drug and\/or target repurposing against trypanosomiasis.\n                  <\/jats:p>","DOI":"10.1371\/journal.pntd.0013719","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:39:32Z","timestamp":1762886372000},"page":"e0013719","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potent kinase inhibitors from the Merck KGaA OGHL: Novel hits against Trypanosoma brucei with potential for repurposing"],"prefix":"10.1371","volume":"19","author":[{"given":"Darline","family":"Dize","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lien F. A.","family":"Moumbock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vianey C.","family":"Tchuenguia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Germaine Y.","family":"Bougnogolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fride S. B.","family":"Nana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra D. W.","family":"Monkam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3147-364X","authenticated-orcid":true,"given":"Fabrice F.","family":"Boyom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"9","key":"pntd.0013719.ref001","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1007\/s00415-019-09425-7","article-title":"Update on human African trypanosomiasis (sleeping sickness)","volume":"266","author":"PGE Kennedy","year":"2019","journal-title":"J Neurol"},{"key":"pntd.0013719.ref002","doi-asserted-by":"crossref","first-page":"621699","DOI":"10.3389\/fvets.2021.621699","article-title":"Epidemiology of Trypanosomiasis in Wildlife-Implications for Humans at the Wildlife Interface in Africa","volume":"8","author":"KI Kasozi","year":"2021","journal-title":"Front Vet Sci"},{"issue":"9683","key":"pntd.0013719.ref003","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"G Priotto","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"pntd.0013719.ref004","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(19)30612-7","article-title":"New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice","volume":"20","author":"AK Lindner","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"pntd.0013719.ref005","article-title":"Chemotherapy for second-stage human African trypanosomiasis: drugs in use","volume":"12","author":"V Lutje","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"pntd.0013719.ref006","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1473-3099(22)00660-0","article-title":"Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2\/3 trial","volume":"23","author":"VK Betu Kumeso","year":"2023","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"pntd.0013719.ref007","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.pt.2024.06.013","article-title":"What is needed to achieve effective and sustainable control of African animal trypanosomosis?","volume":"40","author":"LJ Morrison","year":"2024","journal-title":"Trends Parasitol"},{"key":"pntd.0013719.ref008","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ejmech.2012.07.038","article-title":"The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing","volume":"62","author":"SO Ochiana","year":"2013","journal-title":"Eur J Med Chem"},{"issue":"2","key":"pntd.0013719.ref009","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/bph.13798","article-title":"Drug repurposing from the perspective of pharmaceutical companies","volume":"175","author":"Y Cha","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"10","key":"pntd.0013719.ref010","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4155\/fmc.11.92","article-title":"Target repurposing for neglected diseases","volume":"3","author":"MP Pollastri","year":"2011","journal-title":"Future Med Chem"},{"issue":"1","key":"pntd.0013719.ref011","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"S Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"pntd.0013719.ref012","doi-asserted-by":"crossref","first-page":"8771","DOI":"10.1038\/srep08771","article-title":"New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource","volume":"5","author":"I Pe\u00f1a","year":"2015","journal-title":"Sci Rep"},{"key":"pntd.0013719.ref013","author":"Merck-KGaA","year":"2025"},{"key":"pntd.0013719.ref014","author":"Merck-KGaA","year":"2025"},{"issue":"6","key":"pntd.0013719.ref015","doi-asserted-by":"crossref","first-page":"985","DOI":"10.2307\/3282883","article-title":"Continuous Cultivation of Trypanosoma brucei Blood Stream Forms in a Medium Containing a Low Concentration of Serum Protein without Feeder Cell Layers","volume":"75","author":"H Hirumi","year":"1989","journal-title":"The Journal of Parasitology"},{"key":"pntd.0013719.ref016","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijpddr.2012.02.002","article-title":"Application of a resazurin-based high-throughput screening assay for the identification and progression of new treatments for human African trypanosomiasis","volume":"2","author":"T Bowling","year":"2012","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"19","key":"pntd.0013719.ref017","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.3390\/molecules27196574","article-title":"Preliminary Structure-Activity Relationship Study of the MMV Pathogen Box Compound MMV675968 (2,4-Diaminoquinazoline) Unveils Novel Inhibitors of Trypanosoma brucei brucei","volume":"27","author":"D Dize","year":"2022","journal-title":"Molecules"},{"issue":"7","key":"pntd.0013719.ref018","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1021\/acs.jcim.1c00135","article-title":"ePharmaLib: A Versatile Library of e-Pharmacophores to Address Small-Molecule (Poly-)Pharmacology","volume":"61","author":"AFA Moumbock","year":"2021","journal-title":"J Chem Inf Model"},{"issue":"1","key":"pntd.0013719.ref019","article-title":"BC-11 is a covalent TMPRSS2 fragment inhibitor that impedes SARS-CoV-2 host cell entry","volume":"356","author":"AFA Moumbock","year":"2023","journal-title":"Arch Pharm (Weinheim)"},{"issue":"2","key":"pntd.0013719.ref020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/prot.10613","article-title":"A hierarchical approach to all-atom protein loop prediction","volume":"55","author":"MP Jacobson","year":"2004","journal-title":"Proteins"},{"issue":"3","key":"pntd.0013719.ref021","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments","volume":"27","author":"GM Sastry","year":"2013","journal-title":"J Comput Aided Mol Des"},{"issue":"7","key":"pntd.0013719.ref022","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1021\/acs.jctc.1c00302","article-title":"OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space","volume":"17","author":"C Lu","year":"2021","journal-title":"J Chem Theory Comput"},{"issue":"7","key":"pntd.0013719.ref023","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"RA Friesner","year":"2004","journal-title":"J Med Chem"},{"issue":"7","key":"pntd.0013719.ref024","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1021\/ci500118s","article-title":"Docking covalent inhibitors: a parameter free approach to pose prediction and scoring","volume":"54","author":"K Zhu","year":"2014","journal-title":"J Chem Inf Model"},{"key":"pntd.0013719.ref025","first-page":"84","author":"KJ Bowers","year":"2006","journal-title":"Molecular dynamics---Scalable algorithms for molecular dynamics simulations on commodity clusters. In: Proceedings of the 2006 ACM\/IEEE conference on Supercomputing - SC \u201906"},{"key":"pntd.0013719.ref026","first-page":"67","article-title":"Zhang et al PRB.pdf","volume":"4","author":"JH Zhang","year":"1999","journal-title":"J Biomol Screen"},{"issue":"7","key":"pntd.0013719.ref027","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1074\/mcp.M800556-MCP200","article-title":"The phosphoproteome of bloodstream form Trypanosoma brucei, causative agent of African sleeping sickness","volume":"8","author":"IRE Nett","year":"2009","journal-title":"Mol Cell Proteomics"},{"issue":"11","key":"pntd.0013719.ref028","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1021\/cb300326z","article-title":"Chemical proteomic analysis reveals the drugability of the kinome of Trypanosoma brucei","volume":"7","author":"MD Urbaniak","year":"2012","journal-title":"ACS Chem Biol"},{"issue":"22","key":"pntd.0013719.ref029","doi-asserted-by":"crossref","first-page":"11280","DOI":"10.1021\/cr500197d","article-title":"Kinases as druggable targets in trypanosomatid protozoan parasites","volume":"114","author":"C Merritt","year":"2014","journal-title":"Chem Rev"},{"issue":"11","key":"pntd.0013719.ref030","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.pt.2022.08.009","article-title":"Distinguishing functions of trypanosomatid protein kinases","volume":"38","author":"M Cayla","year":"2022","journal-title":"Trends Parasitol"},{"key":"pntd.0013719.ref031","volume-title":"2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders","author":"C Garcia-Echeverria","year":"2005"},{"issue":"1","key":"pntd.0013719.ref032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003886","article-title":"Regulators of Trypanosoma brucei cell cycle progression and differentiation identified using a kinome-wide RNAi screen","volume":"10","author":"NG Jones","year":"2014","journal-title":"PLoS Pathog"},{"issue":"11","key":"pntd.0013719.ref033","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1021\/acsmedchemlett.3c00212","article-title":"How Ligands Interact with the Kinase Hinge","volume":"14","author":"Z Zhao","year":"2023","journal-title":"ACS Med Chem Lett"},{"key":"pntd.0013719.ref034","doi-asserted-by":"crossref","first-page":"13128","DOI":"10.1038\/ncomms13128","article-title":"Stoichiometric and irreversible cysteine-selective protein modification using carbonylacrylic reagents","volume":"7","author":"B Bernardim","year":"2016","journal-title":"Nat Commun"},{"key":"pntd.0013719.ref035","article-title":"Hypothemycin, a fungal natural product, identifies therapeutic targets in Trypanosoma brucei [corrected]","volume":"2","author":"M Nishino","year":"2013","journal-title":"Elife"},{"issue":"10","key":"pntd.0013719.ref036","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41564-020-0745-6","article-title":"Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors","volume":"5","author":"M Saldivia","year":"2020","journal-title":"Nat Microbiol"},{"key":"pntd.0013719.ref037","volume-title":"3-([1,2,3]triazole-4-yl)-pyrrolo[2,3-b]pyridine derivates","author":"D Dorsch","year":"2010"},{"issue":"6","key":"pntd.0013719.ref038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001151","article-title":"SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis","volume":"5","author":"RT Jacobs","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"pntd.0013719.ref039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000923","article-title":"Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness","volume":"4","author":"E Torreele","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"7619","key":"pntd.0013719.ref040","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"S Khare","year":"2016","journal-title":"Nature"},{"issue":"20","key":"pntd.0013719.ref041","doi-asserted-by":"crossref","first-page":"12254","DOI":"10.1039\/D1RA01480C","article-title":"Medicinal chemistry perspectives of 1,2,3,4-tetrahydroisoquinoline analogs - biological activities and SAR studies","volume":"11","author":"Faheem","year":"2021","journal-title":"RSC Adv"},{"key":"pntd.0013719.ref042","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejmech.2014.07.103","article-title":"Synthesis of pyrazoline-thiazolidinone hybrids with trypanocidal activity","volume":"85","author":"D Havrylyuk","year":"2014","journal-title":"Eur J Med Chem"},{"key":"pntd.0013719.ref043","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejmech.2019.04.052","article-title":"Thiazolidinone\/thiazole based hybrids - New class of antitrypanosomal agents","volume":"174","author":"A Kryshchyshyn","year":"2019","journal-title":"Eur J Med Chem"},{"issue":"9","key":"pntd.0013719.ref044","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1021\/acsmedchemlett.2c00170","article-title":"Pyrimido[5,4-d]pyrimidine-Based Compounds as a Novel Class of Antitrypanosomal and Antileishmanial Agents","volume":"13","author":"A Lopes","year":"2022","journal-title":"ACS Med Chem Lett"},{"issue":"9","key":"pntd.0013719.ref045","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00706-020-02674-7","article-title":"New 2-aminopyrimidine derivatives and their antitrypanosomal and antiplasmodial activities","volume":"151","author":"M Hoffelner","year":"2020","journal-title":"Monatsh Chem"},{"issue":"6","key":"pntd.0013719.ref046","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/cmdc.202000616","article-title":"Synthesis and Structure-Activity Relationships of Imidazopyridine\/Pyrimidine- and Furopyridine-Based Anti-infective Agents against Trypanosomiases","volume":"16","author":"DG Silva","year":"2021","journal-title":"ChemMedChem"},{"key":"pntd.0013719.ref047","doi-asserted-by":"crossref","first-page":"1390705","DOI":"10.3389\/fphar.2024.1390705","article-title":"Repurposing the Open Global Health Library for the discovery of novel Mpro destabilizers with scope as broad-spectrum antivirals","volume":"15","author":"F Castillo","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"pntd.0013719.ref048","doi-asserted-by":"crossref","first-page":"8272","DOI":"10.1038\/s41467-024-52658-y","article-title":"Identification of potent and orally efficacious phosphodiesterase inhibitors in Cryptosporidium parvum-infected immunocompromised male mice","volume":"15","author":"J Ajiboye","year":"2024","journal-title":"Nat Commun"},{"issue":"9","key":"pntd.0013719.ref049","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1021\/acsinfecdis.3c00138","article-title":"A Pyridyl-Furan Series Developed from the Open Global Health Library Block Red Blood Cell Invasion and Protein Trafficking in Plasmodium falciparum through Potential Inhibition of the Parasite\u2019s PI4KIIIB Enzyme","volume":"9","author":"DB Ling","year":"2023","journal-title":"ACS Infect Dis"},{"issue":"1","key":"pntd.0013719.ref050","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13071-024-06648-0","article-title":"Merck Open Global Health Library in vitro screening against Schistosoma mansoni identified two new substances with antischistosomal activities for further development","volume":"18","author":"ME Ueberall","year":"2025","journal-title":"Parasit Vectors"},{"issue":"17","key":"pntd.0013719.ref051","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.1016\/j.bmcl.2013.06.071","article-title":"Discovery of 7-azaindole based anaplastic lymphoma kinase (ALK) inhibitors: wild type and mutant (L1196M) active compounds with unique binding mode","volume":"23","author":"VR Gummadi","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"pntd.0013719.ref052","doi-asserted-by":"crossref","first-page":"102247","DOI":"10.1016\/j.jbc.2022.102247","article-title":"Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors","volume":"298","author":"C Arter","year":"2022","journal-title":"J Biol Chem"},{"issue":"10","key":"pntd.0013719.ref053","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164895","article-title":"Inhibition of an Erythrocyte Tyrosine Kinase with Imatinib Prevents Plasmodium falciparum Egress and Terminates Parasitemia","volume":"11","author":"KR Kesely","year":"2016","journal-title":"PLoS One"},{"key":"pntd.0013719.ref054","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/abr.abr_58_19","article-title":"Evaluation of Different Concentrations of Imatinib on the Viability of Leishmania major: An In Vitro Study","volume":"8","author":"M Moslehi","year":"2019","journal-title":"Adv Biomed Res"},{"issue":"1","key":"pntd.0013719.ref055","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0169-4758(99)01560-4","article-title":"Anti-sleeping sickness drugs and cancer chemotherapy","volume":"16","author":"SV Barrett","year":"2000","journal-title":"Parasitol Today"},{"issue":"4","key":"pntd.0013719.ref056","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000658","article-title":"The genome sequence of Trypanosoma brucei gambiense, causative agent of chronic human african trypanosomiasis","volume":"4","author":"AP Jackson","year":"2010","journal-title":"PLoS Negl Trop Dis"}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0013719","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T18:46:25Z","timestamp":1763405185000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0013719"}},"subtitle":[],"editor":[{"given":"Sarman","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":56,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0013719","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]}}}